Pharmalucence, Inc. has entered into an agreement with Lantheus Medical Imaging to manufacture DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension for contrast-enhanced echocardiography. Pharmalucence will provide manufacturing at its new drug production facility in Billerica, MA for a minimum of 10 years.
Ed Connolly, chief operating officer of Pharmalucence, said, “Pharmalucence has established a world-class manufacturing facility here in New England, which has been recognized by companies who choose to outsource their manufacturing. We are extremely pleased to partner with Lantheus, a local company with a reputation for exceptional product innovation and quality, for the supply of DEFINITY.”
“Our manufacturing agreement with Pharmalucence is a vital component of our plan to secure long-term supply of DEFINITY,” said Jeff Bailey, Lantheus president and chief executive officer. “We look forward to working with Pharmalucence, who has a shared commitment to deliver the highest quality products to the customers and patients who benefit from DEFINITY.”
Pharmalucence Wins Lantheus Contract
By Kristin Brooks
Published December 10, 2013
Related Breaking News
Related Online Exclusives